Results 121 to 130 of about 85,259 (288)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis

open access: yesCancer Communications, EarlyView.
Abstract Background Colorectal cancer liver metastasis (CRLM) is characterized by an immunosuppressive microenvironment and a blunted response to immunotherapy. Notably, tumor‐associated macrophages (TAMs) play a critical role in modulating immune responses and exhibit significant heterogeneity in CRLM.
Yizhi Zhan   +11 more
wiley   +1 more source

Preliminary assessment of various additives on the specific reactivity of anti- rHBsAg monoclonal antibodies [PDF]

open access: yes, 2015
Background: Antibodies have a wide application in diagnosis and treatment. In order to maintain optimal stability of various functional parts of antibodies such as antigen binding sites, several approaches have been suggested.
Mohammadi, S.   +3 more
core  

Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, in Healthy Chinese Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Galcanezumab is used in several regions, including the United States, Europe, and China, as a preventive treatment for migraine. This study aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of galcanezumab in healthy Chinese participants.
Jingjing Wang   +8 more
wiley   +1 more source

Monitoring Treatment‐Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow Cytometry

open access: yesCytometry Part A, EarlyView.
ABSTRACT Multiple sclerosis (MS) is a chronic, immune‐mediated autoimmune disease characterized by the infiltration of autoreactive T cells and other inflammatory immune cells from the periphery into the central nervous system. Currently, there is no cure for MS, and treatment consists of disease‐modifying therapies (DMTs), most of which modify or ...
Katharina Robichon   +4 more
wiley   +1 more source

Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates. [PDF]

open access: yes, 2019
Tumor metastasis into the central nervous system (CNS) and lymph nodes (LNs) is a major obstacle for effective therapies. Therapeutic monoclonal antibodies (mAb) have revolutionized tumor treatment; however, their efficacy for treating metastatic tumors ...
Chen, Irvin SY   +18 more
core   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Emerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects

open access: yesFood Frontiers, EarlyView.
Food allergy is a rising global health concern with limited treatment options beyond allergen avoidance and emergency care. This review explores the evolving therapeutic landscape, highlighting advances in allergen immunotherapy, biologics such as monoclonal antibodies, and emerging vaccine‐based approaches.
Ayesha Zahid   +3 more
wiley   +1 more source

Cetuximab Hypersensitivity in the Setting of Asymptomatic Alpha‐Gal Sensitization

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Alpha‐gal syndrome is an allergic condition resulting from the bite of the Lonestar tick in the southeastern US that leads to sensitization to mammalian products containing the oligosaccharide galactose‐alpha‐1,3‐galactose (alpha‐gal).
Alexander G. Emerson   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy